Hospital Universitario 12 de Octubre-ko ikertzaileekin lankidetzan egindako argitalpenak (19)

2022

  1. Lactoferrin as Immune-Enhancement Strategy for SARS-CoV-2 Infection in Alzheimer’s Disease Patients

    Frontiers in Immunology, Vol. 13

2021

  1. Standardizing salivary lactoferrin measurements to obtain a robust diagnostic biomarker for alzheimer’s disease

    Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 13, Núm. 1

2020

  1. Decreased salivary lactoferrin levels are specific to Alzheimer's disease

    EBioMedicine, Vol. 57, pp. 102834

2018

  1. Intranasal administration of TAT-conjugated lipid nanocarriers loading GDNF for Parkinson’s disease

    Molecular Neurobiology, Vol. 55, Núm. 1, pp. 145-155

2017

  1. Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin

    Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 8, pp. 131-138

2015

  1. Chitosan coated nanostructured lipid carriers for brain delivery of proteins by intranasal administration

    Colloids and Surfaces B: Biointerfaces, Vol. 134, pp. 304-313

  2. Enhanced hippocampal neurogenesis in APP/Ps1 mouse model of alzheimer’s disease after implantation of VEGF-loaded PLGA nanospheres

    Current Alzheimer Research, Vol. 12, Núm. 10, pp. 932-940

  3. Intranasal PRGF-Endoret enhances neuronal survival and attenuates NF-κB-dependent inflammation process in a mouse model of Parkinson's disease

    Journal of Controlled Release, Vol. 203, pp. 170-180

2014

  1. Plasma rich in growth factors (PRGF-Endoret) reduces neuropathologic hallmarks and improves cognitive functions in an Alzheimer's disease mouse model

    Neurobiology of Aging, Vol. 35, Núm. 7, pp. 1582-1595

2013

  1. Intranasal Delivery of Plasma and Platelet Growth Factors Using PRGF-Endoret System Enhances Neurogenesis in a Mouse Model of Alzheimer's Disease

    PLoS ONE, Vol. 8, Núm. 9

  2. VEGF-releasing biodegradable nanospheres administered by craniotomy: A novel therapeutic approach in the APP/Ps1 mouse model of Alzheimer's disease

    Journal of Controlled Release, Vol. 170, Núm. 1, pp. 111-119

2012

  1. Encapsulated VEGF-secreting cells enhance proliferation of neuronal progenitors in the hippocampus of AβPP/PS1 mice

    Journal of Alzheimer's Disease, Vol. 29, Núm. 1, pp. 187-200

2010

  1. The effect of encapsulated VEGF-secreting cells on brain amyloid load and behavioral impairment in a mouse model of Alzheimer's disease

    Biomaterials, Vol. 31, Núm. 21, pp. 5608-5618

2008

  1. Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy

    Clinical Pharmacokinetics, Vol. 47, Núm. 3, pp. 173-180

2007

  1. In vitro AN69 and polysulphone membrane permeability to ceftazidime and in vivo pharmacokinetics during continuous renal replacement therapies

    Chemotherapy, Vol. 53, Núm. 3, pp. 194-201

2005

  1. Cefepime and continuous renal replacement therapy (CRRT): In vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients

    Clinical Therapeutics, Vol. 27, Núm. 5, pp. 599-608

  2. Influence of renal function on the pharmacokinetics of piperacillin/ tazobactam in intensive care unit patients during continuous venovenous hemofiltration

    Journal of Clinical Pharmacology, Vol. 45, Núm. 2, pp. 168-176

  3. Meropenem and continuous renal replacement therapy: In vitro permeability of 2 continuous renal replacement therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patients

    Journal of Clinical Pharmacology, Vol. 45, Núm. 11, pp. 1294-1304

  4. Quantification and stability of piperacillin and tazobactam in plasma and ultrafiltrate from patients undergoing continuous venovenous hemofiltration by HPLC

    Biomedical Chromatography, Vol. 19, Núm. 8, pp. 570-578